Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091882 · ClinicalTrials.gov registry record · Phase 4
Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
A Phase 4 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT02091882 is a Phase 4 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 30 participants.
The verdict
NCT02091882, a Phase 4 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.
Interventions
- DRUG Placebo
- COMBINATION_PRODUCT Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-03-21 |
| Est. Completion | 2014-04-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091882
The ClinicalTrials.gov registry entry for NCT02091882 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02091882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091882 about?
NCT02091882 is a clinical study titled "Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)". The purpose of this study was to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.
What is the current status of trial NCT02091882?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2014-03-21. Estimated completion is 2014-04-18.
What interventions are being tested in trial NCT02091882?
The interventions under investigation include: Placebo (DRUG), Combination product of Aripiprazole + IEM + Sensor + MIND1 Application (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02091882?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.